Chronic Idiopathic Constipation (CIC) Epidemiology Forecast 2025-2034

Chronic idiopathic constipation (CIC) epidemiology forecast indicates that chronic idiopathic constipation is one of the most prevalent gastrointestinal disorders, which is observed to be more common in women and older adults. The condition affects about 14% of the population worldwide, as per Black, C. J., & Ford, A. C. (2018). Chronic idiopathic constipation is known to have 3 subtypes: normal transit constipation, slow transit constipation, and dyssynergic defecation, of which normal transit constipation is the most prevalent subtype.

Chronic Idiopathic Constipation (CIC) Epidemiology Forecast Report Coverage

The “Chronic Idiopathic Constipation (CIC) Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of chronic idiopathic constipation (CIC). It projects the future incidence and prevalence rates of chronic idiopathic constipation (CIC) cases across various populations. The study covers age and type as major determinants of the chronic idiopathic constipation (CIC) population. The report highlights patterns in the prevalence of chronic idiopathic constipation (CIC) over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on chronic idiopathic constipation (CIC) epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Chronic Idiopathic Constipation (CIC) Understanding: Disease Overview

Chronic idiopathic constipation refers to a gastrointestinal condition characterized by long-term difficulty in passing stools, abdominal discomfort, and infrequent bowel movements. The exact cause of chronic idiopathic constipation is unknown. The symptoms of this condition may be exacerbated by lifestyle factors, such as a low-fiber diet, dehydration, lack of physical activity, and certain medications. The Rome IV criteria, which are widely used in diagnosing functional gastrointestinal disorders, are also used for identifying chronic idiopathic constipation. The condition is known to affect daily activities, mood, and overall well-being, leading to frustration, anxiety, and social discomfort. Early diagnosis and appropriate management can help the affected individuals improve symptoms and enhance their quality of life.

Chronic Idiopathic Constipation (CIC) Epidemiology Perspective

The chronic idiopathic constipation (CIC) epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for the chronic idiopathic constipation (CIC) epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for the disease and their trends. The chronic idiopathic constipation (CIC) detailed epidemiology segmentation is broken down into specific categories, such as the total diagnosed cases across different age groups and patient pools.

• A 2023 United States survey found Rome IV chronic idiopathic constipation is more common (6.0%) than Rome IV opioid-induced constipation (1.7%) and opioid-exacerbated constipation (0.4%).
• According to a population-based survey on chronic constipation in the United States (2020), 3 out of 5 Americans with constipation have never discussed their symptoms with a healthcare provider, showing that most of the affected patients rely on over-the-counter treatments, with low use of prescription medications.
• As per Black, C. J., & Ford, A. C. (2018), chronic idiopathic constipation affects 14% of the population globally. It has three subtypes: normal transit constipation, slow transit constipation, and dyssynergic defecation, out of which normal transit constipation is the most common subtype.
• Various studies show that chronic idiopathic constipation affects 10% to 17% of the global population. The condition is more common in women and older adults and often leads to debilitating symptoms.

Country-wise Chronic Idiopathic Constipation (CIC) Epidemiology Segment

The chronic idiopathic constipation (CIC) epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of chronic idiopathic constipation (CIC) varies significantly between countries due to differences in diet, lifestyle, genetic predisposition, healthcare access, and diagnostic criteria. In the United States, around 35 million adults may experience chronic idiopathic constipation. It is reported to be more common in women (56%) and adults over 35 years (84%). Studies also reveal that Caucasians are more affected (82%) than other races and ethnicities.

Chronic Idiopathic Constipation (CIC): Treatment Overview

Chronic idiopathic constipation is typically treated with a combination of medications, lifestyle changes, and in some cases, medical procedures. Over-the-counter laxatives, including osmotic laxatives (polyethylene glycol, lactulose), stimulant laxatives (bisacodyl, senna), and lubricant laxatives (mineral oil), are commonly used to treat the condition. Prescription medications such as prokinetic agents, 5-HT4 receptor agonists, and chloride channel activators are given to patients who do not respond to over-the-counter treatments. Advanced and alternative therapies include biofeedback therapy for patients with pelvic floor dysfunction, neuromodulation techniques (sacral nerve stimulation) for treatment-resistant cases, and surgery for severe, unresponsive chronic idiopathic constipation (CIC).

Key Questions Answered

• What are the key findings of chronic idiopathic constipation (CIC) epidemiology in the 8 major markets?
• What will be the total number of patients with chronic idiopathic constipation (CIC) across the 8 major markets during the forecast period?
• What was the country-wise chronic idiopathic constipation (CIC) epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of chronic idiopathic constipation (CIC) patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of chronic idiopathic constipation (CIC) during the forecast period of 2025-2034?
• What are the currently available treatments in the chronic idiopathic constipation (CIC) market?
• What are the disease risks, signs, symptoms, and unmet needs of chronic idiopathic constipation (CIC)?

Scope of the Chronic Idiopathic Constipation (CIC) Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of chronic idiopathic constipation (CIC) based on several factors.
• The Chronic Idiopathic Constipation (CIC) Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The chronic idiopathic constipation (CIC) report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.